By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Vertex Pharmaceuticals Incorporated 

Research & Development
275 Armand-Frappier
Laval  Quebec  H7V 4A7  Canada
Phone: 450-978-7700 Fax: 450-978-7972


SEARCH JOBS




The Science of Possibility.

Vertex Canada is home to innovators in biopharmaceutical research and development. We employ approximately 60 professionals at our research facility in Laval, Quebec, including approximately 45 scientists focused on drug discovery and development activities.

Vertex’s Canadian team is focused on research activities related to inflammatory bowel diseases (IBD), which include Crohn’s Disease and ulcerative colitis. Vertex Canada features a diverse scientific team covering all of our major disciplines and fosters strong cross-functional teams between departments.

Our workplace reflects the rich multiculturalism of the area, which our employees point to as a key advantage of working here. Scientists and researchers from our Laval location have strong collaborative relationships with academic institutions in the area, as well as with our other Vertex locations worldwide.

As part of Vertex’s global network of science research, the Laval site is positioned to continue its quarter century of Canadian contribution to discovering new possibilities in medicine and advancing Canada’s scientific research workforce.

For more information on Vertex, please visit www.vrtx.com. For information on career opportunities with Vertex Canada, please visit www.careers.vrtx.com/.


Key Statistics


Email:
Ownership: Public

Web Site: Vertex (Canada)
Employees:
Symbol: VRTX
 









Company News
Vertex Pharmaceuticals Incorporated (VRTX) To Present At Upcoming Investor Conferences 2/12/2015 7:46:58 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Full-Year And Fourth Quarter 2014 Financial Results And Provides Guidance For 2015 1/29/2015 11:06:46 AM
Vertex Pharmaceuticals Incorporated (VRTX) Outlines 2015 Business Priorities To Support The Development, Approval And Launch Of New Medicines For The Treatment Of People With Cystic Fibrosis 1/12/2015 1:26:41 PM
Vertex Pharmaceuticals Incorporated (VRTX) Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2014 Financial Results 1/7/2015 9:46:41 AM
Royalty Pharma Buys Royalties On Vertex Pharmaceuticals Incorporated (VRTX) Drugs For $3.3 Billion 11/19/2014 5:47:18 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Present At The Credit Suisse Healthcare Conference On November 11 10/31/2014 8:56:44 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Third Quarter 2014 Financial Results 10/29/2014 8:50:50 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Present At Morgan Stanley (MST) Global Healthcare Conference On September 10 9/3/2014 1:51:40 PM
Vertex Pharmaceuticals Incorporated (VRTX) Receives European Approval For KALYDECO™ (ivacaftor) In Eight Non-G551D Gating Mutations 8/1/2014 10:27:36 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Second Quarter 2014 Financial Results And Provides Updates On Key Research And Development Programs 7/30/2014 10:41:59 AM
123456
//-->